Intercept Pharmaceuticals, a biopharmaceutical company and wholly-owned subsidiary of Alfasigma, announced new data from a sub-analysis of the landmark Phase 3 POISE trial evaluating the impact of obeticholic acid on
Intercept Pharmaceuticals, a biopharmaceutical company and wholly-owned subsidiary of Alfasigma, announced new data from a sub-analysis of the landmark Phase 3 POISE trial evaluating the impact of obeticholic acid on
RBC Capital analyst Brian Abrahams maintained a Hold rating on Intercept Pharma (ICPT – Research Report) on November 6 and set a price target of $19.00. The company’s shares closed
BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) — Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc.
Alfasigma and Intercept Pharmaceuticals announced the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc. Following the completion of Alfasigma’s successful tender offer
The European Medicines Agency’s human medicines committee has started a review of Intercept’s Ocaliva, used to treat adults with primary biliary cholangitis. PBC is an autoimmune condition that causes gradual